Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sumanta Kumar Pal

Showing results (81-90 of 94) with videos related to

Pageof 10
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 24, 2017
Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell CancerToni K Choueiri, Elizabeth Plimack, Hendrik-Tobias Arkenau, et al.
Oncotarget|May 24, 2016
Relationship of smoking status to genomic profile, chemotherapy response and clinical outcome in patients with advanced urothelial carcinomaMonika Joshi, Monali Vasekar, Petros Grivas, et al.
JCO Precision Oncology|May 18, 2026
Use of ALK Inhibitors in Patients With Nonlung Malignancies Bearing <i>ALK</i> Alteration Prolongs Treatment DurationVitor Abreu de Góes, Matthew Lee, Miguel Zugman, et al.
Cancer Research Communications|June 30, 2026
Comprehensive Profiling of Cell Surface Proteins in Testicular Germ Cell TumorsHedyeh Ebrahimi, Ali Moradi, Regina Barragan-Carrillo, et al.
European Urology|April 26, 2026
Comprehensive Genomic and Transcriptomic Characterization of Matched Primary and Recurrent Tumors in High-risk Localized Renal Cell CarcinomaWenxin Xu, Brian I Rini, Laurence Albiges, et al.
Lancet (London, England)|September 13, 2022
Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trialSumanta Kumar Pal, Robert Uzzo, Jose Antonio Karam, et al.
Frontiers in Oncology|May 20, 2026
International metastatic renal cell carcinoma database consortium classification and regression tree analysis to characterize objective response rates to first line in metastatic renal cell carcinomaMartin Zarba, Dylan O'Sullivan, David Maj, et al.
Clinical Genitourinary Cancer|March 8, 2020
Unfavorable Cancer-specific Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients With Bladder Cancer and Squamous Cell Variant: A Multi-institutional StudyMarco Bandini, Filippo Pederzoli, Russell Madison, et al.
Lancet (London, England)|June 8, 2023
Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trialSumanta Kumar Pal, Laurence Albiges, Piotr Tomczak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 6, 2016
Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical OncologyDon S Dizon, Lada Krilov, Ezra Cohen, et al.
Pageof 10

Showing results (81-90 of 94) with videos related to

Sort By:
Pageof 10
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 24, 2017
Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell CancerToni K Choueiri, Elizabeth Plimack, Hendrik-Tobias Arkenau, et al.
Oncotarget|May 24, 2016
Relationship of smoking status to genomic profile, chemotherapy response and clinical outcome in patients with advanced urothelial carcinomaMonika Joshi, Monali Vasekar, Petros Grivas, et al.
JCO Precision Oncology|May 18, 2026
Use of ALK Inhibitors in Patients With Nonlung Malignancies Bearing <i>ALK</i> Alteration Prolongs Treatment DurationVitor Abreu de Góes, Matthew Lee, Miguel Zugman, et al.
Cancer Research Communications|June 30, 2026
Comprehensive Profiling of Cell Surface Proteins in Testicular Germ Cell TumorsHedyeh Ebrahimi, Ali Moradi, Regina Barragan-Carrillo, et al.
European Urology|April 26, 2026
Comprehensive Genomic and Transcriptomic Characterization of Matched Primary and Recurrent Tumors in High-risk Localized Renal Cell CarcinomaWenxin Xu, Brian I Rini, Laurence Albiges, et al.
Lancet (London, England)|September 13, 2022
Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trialSumanta Kumar Pal, Robert Uzzo, Jose Antonio Karam, et al.
Frontiers in Oncology|May 20, 2026
International metastatic renal cell carcinoma database consortium classification and regression tree analysis to characterize objective response rates to first line in metastatic renal cell carcinomaMartin Zarba, Dylan O'Sullivan, David Maj, et al.
Clinical Genitourinary Cancer|March 8, 2020
Unfavorable Cancer-specific Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients With Bladder Cancer and Squamous Cell Variant: A Multi-institutional StudyMarco Bandini, Filippo Pederzoli, Russell Madison, et al.
Lancet (London, England)|June 8, 2023
Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trialSumanta Kumar Pal, Laurence Albiges, Piotr Tomczak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 6, 2016
Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical OncologyDon S Dizon, Lada Krilov, Ezra Cohen, et al.
Pageof 10